Skip to content
Review Open access

Von Willebrand Disease (VWD) 100 years after its first description: the research of Italian investigators for a better management of VWD patients

Oct 2026 · Bleeding Thrombosis and Vascular Biology · Vol 5 · 0 citations · 138 references

TL;DR

Despite major efforts by experts, who recently summarized their recommendations in the International Guidelines on VWD diagnosis and therapy, there are still many unmet needs in this disease management.

Abstract

Since the first description of the von Willebrand disease (VWD) families by Erik von Willebrand in 1926, VWD has been considered an inherited bleeding disorder completely different from hemophilia, already known for many years. The pivotal role of the adhesive glycoprotein von Willebrand factor in the early phases of hemostasis has been progressively unraveled in numerous publications. Still, actual progress in the clinical management of patients with VWD has always lagged that achieved in patients with hemophilia. After the pioneering studies of the first 50 years (1926-1975), the pathophysiology and diagnostics of patients with VWD became better distinguished from those with hemophilia. However, only in the last 50 years (1976-2025) have the basic and clinical aspects of VWD been clearly defined, with the scientific contributions of Italian investigators. Thanks to their research in collaboration with colleagues from Europe and the US, management of VWD patients improved significantly. In this review article, the most important milestones achieved in the diagnosis and treatment of VWD will be presented. Despite major efforts by experts, who recently (2021) summarized their recommendations in the International Guidelines on VWD diagnosis and therapy, there are still many unmet needs in this disease management. Indeed, the recommendations of the International Guidelines must be translated into current national practice by using a simplified diagnostic approach, as proposed recently by the joint AICE (Italian Association of Hemophilia Centers) and SISET (Italian Society for the Study of Hemostasis and Thrombosis) Italian Guidelines and by organizing structured clinical observation not only of severe VWD but especially of the more frequent mild-to-moderate types.

Read PDF

Similar papers

Open access Oct 2026

100 Years of von Willebrand Disease (VWD): Comparison of Historical and Contemporary von Willebrand Factor (VWF) Activity Assays in the Laboratory Identification of VWD.

INTRODUCTION von Willebrand disease (VWD) is a prevalent bleeding disorder resulting from deficiencies and/or defects in von Willebrand factor (VWF). Accurately diagnosing VWD, particularly distinguishing between qualitative defects (types 2A, 2B, 2 M, and 2N) and quantitative defects (types 1 and 3), poses challenges...

E. Favaloro, Sandya Arunachalam, Mahzuza Salwa et al. · 0 citations
Open access Oct 2026

CO-07 | ITALIAN RESOURCE USE IN MILD HEMOPHILIA A AND TYPE 1 VON WILLEBRAND DISEASE

Introduction. Hemophilia A and von Willebrand disease (VWD) are the most common inherited bleeding disorders, resulting from low or dysfunctional factor VIII (FVIII) and von Willebrand factor (VWF), respectively. The purpose of the following analysis is to quantify the potential savings through desmopressin (DDAVP) use...

Alessandro Gringeri · 0 citations
Open access Mar 2011

Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease

Type 3 von Willebrand disease (VWD3) is due to a virtually complete deficiency of von Willebrand factor (VWF), and it is inherited as an autosomal recessive trait: heterozygous relatives have mild or no bleeding symptoms. The prevalence of VWD3 is very low, ranging from 0.1 to 5.3 per million population. VWD3 patients...

L. Baronciani, A. Federici, J. Eikenboom · 5 citations
Open access Oct 2026

CO-64 | REAPPRAISAL OF DESMOPRESSIN FOR MANAGEMENT OF MILD/MODERATE VON WILLEBRAND DISEASE: RESULTS OF A RETROSPECTIVE ANALYSIS IN 127 ITALIAN PATIENTS SUGGEST FURTHER ORGANIZATION OF PROSPECTIVE OBSERVATIONAL STUDIES TO PREDICT DESMOPRESSIN FAILURE WITH IMMEDIATE VWF CONCENTRATES REQUIREMENT

Background. Desmopressin (DDAVP) has always been considered the treatment of choice for patients with mild/moderate von Willebrand disease (VWD), but no standardized criteria have been reported so far to predict the benefits/limits of DDAVP in the management of a very large cohort of VWD.Aims. To establish correct indi...

A. B. Federici · 0 citations
Review Open access Oct 2026

CO-01 | BLEEDING EVENTS IN MILD HEMOPHILIA A AND VON WILLEBRAND DISEASE TYPE 1 YEARLY TREATABLE WITH DESMOPRESSIN IN ITALY

Background. Subcutaneous and intranasal desmopressin is safe and effective in type 1 VWD and particularly convenient for pediatric use and home treatment. Thus, it can reduce in-hospital admissions and inherent costs and favor adherence and the prompt control of bleeding. Nevertheless, it is often underused or unavaila...

Alessandro Gringeri · 0 citations
Open access Oct 2026

Clinical efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII in long-term prophylaxis study in patients older than 6 years with severe von Willebrand disease

Benefits of long-term prophylaxis (LTP) in patients with severe von Willebrand disease (VWD) were well established by several studies. However, data on treatment modalities to gain optimal dosing and infusion schedule are limited. To assess the efficacy and safety of LTP with a plasma-derived von Willebrand...

Cédric Hermans, B. Meddeb, Q. Van Thillo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.